Skip to content

Dextromethorphan-bupropion-associated pharmacovigilance signals based on the FAERS database: An observational study.

Ruixue Liu, Chunxiao Liu, Chunhui Li, Di Hu, Longkun Wang, Zhenmin Li, Dianwei Feng, Tongxin Guo

Medicine June 26, 2026 DOI: 10.1097/md.0000000000049464 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Observational pharmacovigilance study using FDA adverse event reporting system data Peer reviewed
Sample size 3,580
Population Adverse events reported for dextromethorphan-bupropion in the FDA adverse event reporting system
Intervention Dextromethorphan-bupropion
Duration 4th quarter of 2022 to 4th quarter of 2024
Topics Depression
Keywords Auvelity Faers Adverse events Dextromethorphan-bupropion
Key findings Dextromethorphan-bupropion is associated with adverse event signals, including psychiatric and nervous system disorders, with 65.3% of signals not listed in the drug's label.

Abstract

Dextromethorphan-bupropion, a novel oral N-methyl-D-aspartate receptor antagonist approved by the Food and Drug Administration in August 2022, launched in the United States in October 2022 for major depressive disorder. We aimed to detect and characterize the adverse events (AEs) of dextromethorphan-bupropion using the FDA adverse event reporting system from the 4th quarter of 2022 to the 4th quarter of 2024. For signal quantification of dextromethorphan-bupropion-related AEs, we used disproportionality methods including the reporting odds ratio, proportional reporting ratio, and multi-item gamma Poisson shrinker algorithms. Our study analyzed 4,804,129 AEs, while 3580 AEs were associated with dextromethorphan-bupropion, which included 266 preferred term signals and 21 system organ classes. These AEs mainly occurred as psychiatric disorders (21.17%), nervous system disorders (20.92%), general disorders, administration site conditions (19.75%), and others. Notably, obsessive rumination (n = 3, reporting odds ratio = 366.02, proportional reporting ratio = 365.71, empirical Bayes geometric mean = 287.56) exhibited the lowest morbidity, whereas the highest signal intensity. Specifically, 65.3% of preferred terms were not explicitly mentioned in the instructions, which suggested the previously unlabeled signals. Dextromethorphan-bupropion poses potential reporting signals of various AEs, though providing therapeutic effects. In clinical applications, practitioners should closely monitor occurrences of psychiatric disorders, nervous system disorders, general disorders, administration site conditions, and other events. Meanwhile, professional clinicians should be alerted to the AEs signals not mentioned in the label to secure clinical use.

Comparable studies

Other observational and cohort studies on depression, most cited first.

Study Year Design Participants
Metacognitive awareness and prevention of relapse in depression: Empirical evidence. Residually depressed patients and nondepressed controls; recovered depressed patients 2002 Observational cohort with intervention components
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Patients with treatment-resistant depression 2017 Observational cohort n = 19
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report Patients with a depressive disorder 2015 Observational study
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder Patients with treatment-resistant major depressive disorder 2012 Observational cohort n = 30
Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome Healthy controls and actively depressed patients with treatment-resistant depression... 2017 Observational cohort n = 59

Citations in the library

Cites 6

and 1 more in the library

Related reading

Explore topics

Depression